Publications by authors named "Marzena Jankowska-Anyszka"

All cells in our body are equipped with receptors to recognize pathogens and trigger a rapid defense response. As a result, foreign molecules are blocked, and cells are alerted to the danger. Among the many molecules produced in response to viral infection are interferon-induced proteins with tetratricopeptide repeats (IFITs).

View Article and Find Full Text PDF
Article Synopsis
  • * New strategies include using 5' end mRNA cap analogues to inhibit eIF4E's overexpression, with promising results from modified cap analogues.
  • * The study reveals that introducing dual modifications in these analogues enhances their effectiveness, signaling progress in developing cancer treatments that target the eIF4E pathway.
View Article and Find Full Text PDF
Article Synopsis
  • mRNA-based drugs are rapidly advancing, particularly as viral vaccines, with potential uses in various diseases due to their easy and adaptable production process.
  • The structure of mRNA components, especially modifications at the 5' cap, significantly influences its effectiveness and longevity in medical applications.
  • This study focuses on synthesizing modified cap analogues and testing these compounds for their ability to act as translation inhibitors and improve mRNA preparation.
View Article and Find Full Text PDF
Article Synopsis
  • Scientists are exploring mRNA as a new class of drugs, particularly for vaccine technology, due to its rapid production and cost-effectiveness.
  • The small cap structure at the 5' end of mRNA is key for protection and efficient use in protein synthesis, enabling various modifications that enhance mRNA activity.
  • Particularly, N2-modified cap analogues demonstrate promising biological properties and translational activity, suggesting potential future applications in cancer treatment and RNA engineering.
View Article and Find Full Text PDF
Article Synopsis
  • The text discusses ProTide technology, a widely used method for developing prodrugs of therapeutic nucleosides in medicinal chemistry.
  • The authors adapted this technology to synthesize bioactive 5'-mRNA cap analogues, which act as inhibitors for cap-dependent translation.
  • The synthesis involved two stages: creating modified guanosine analogues and turning them into prodrugs, which were then tested for their activation, inhibitory effects, and ability to cross cell membranes.
View Article and Find Full Text PDF
Article Synopsis
  • mRNA-based vaccines are innovative technologies that have recently gained attention from research centers and pharmaceutical companies, offering advantages over DNA-based vaccines due to their safety and flexibility.
  • These vaccines avoid risks of genomic integration and can be easily engineered to improve their efficiency and stability.
  • The study discusses the use of N2 modified dinucleotide cap analogs in mRNA, which enhance translation efficiency and proper attachment, showing promising results in both in vitro and human cell experiments.
View Article and Find Full Text PDF
Article Synopsis
  • Targeted anticancer drugs face challenges, particularly regarding eukaryotic translation initiation factor 4E (eIF4E), which is overexpressed in various cancers and promotes tumor growth and spread.
  • To inhibit eIF4E, researchers are using cap analogs, but they struggle to deliver these because they can't easily penetrate cell membranes.
  • By attaching cap analogs to a cell-penetrating peptide derived from HIV (TAT), the study found that these conjugates could enter breast cancer cells and effectively reduce cap-dependent translation without hindering cell growth or survival.
View Article and Find Full Text PDF
Article Synopsis
  • The text discusses the synthesis of new isoxazole-containing 5' mRNA cap analogues through a cycloaddition reaction.
  • These analogues can inhibit cap-dependent translation in lab conditions and utilize an isoxazolic ring for binding instead of guanine.
  • The findings contribute to the development of potential anticancer treatments by informing the design of new compounds.
View Article and Find Full Text PDF
Article Synopsis
  • mRNA degradation plays a crucial role in regulating gene expression, specifically through the 3' → 5' decay pathway involving the exosome complex and decapping enzymes.
  • The study focuses on the decapping scavenger enzyme DcpS from humans, Caenorhabditis elegans (CeDcpS), and Aspergillus species (AsDcpS), examining their activity toward modified cap analogues.
  • Results showed that longer alkyl chains on cap analogues led to resistance against hydrolysis by hDcpS and CeDcpS, likely due to weaker binding interactions between the modified caps and the enzymes.
View Article and Find Full Text PDF
Article Synopsis
  • Advances in gene manipulation techniques, particularly DNA therapy, are being significantly enhanced by new mRNA technologies that improve particle stability and translation efficiency.
  • Recent studies focused on modifying mRNA cap structures, specifically at the N2 position of 7-methylguanosine, which increased translation inhibition and led to the design of new dinucleotide cap analogs.
  • In testing these new cap analogs in rabbit reticulocyte lysate and HEK293 cell lines, the results showed improved translational properties and stability over conventional caps, with one analog demonstrating strong translation inhibition.
View Article and Find Full Text PDF
Article Synopsis
  • - Human Nudt16 (hNudt16) is an enzyme that breaks down various RNA-related substrates, with a particular focus on its decapping activity in the nucleolus, specifically targeting U8 snoRNA.
  • - Recent findings show that hNudt16 localizes to the cytoplasm and plays a role in RNA turnover, similar to the enzyme Dcp2, by hydrolyzing cap structures in RNA.
  • - The study reveals that hNudt16 is more effective at breaking down dinucleotide cap analogs and short capped oligonucleotides that contain guanine, indicating its broader specificity than previously understood.
View Article and Find Full Text PDF
Article Synopsis
  • Cell-penetrating peptides (CPPs) can transport therapeutic agents across cell membranes, but their entry mechanisms are not fully understood.
  • This study specifically investigates the membrane permeability sequence (MPS) peptide linked to 5' mRNA cap analogues, finding that the MPS peptide can translocate across membranes of giant unilamellar vesicles (GUVs).
  • The research demonstrates that while the MPS peptide itself can cross membranes, passive translocation does not occur for its conjugates, although some permeability was seen with mononucleotide analogues, emphasizing the importance of using artificial membranes for studying these mechanisms.
View Article and Find Full Text PDF
Article Synopsis
  • - Snurportin 1 is a protein that helps transport specific small nuclear RNAs into the nucleus, influencing how these RNA complexes function in the cell.
  • - Researchers created new cap analogues to better understand how snurportin recognizes and binds to the TMG (trimethylguanosine) structure on RNA.
  • - The study found that snurportin is very selective for the TMG-cap, favoring its specific structure due to its stiffness and compactness, which are crucial for binding.
View Article and Find Full Text PDF
Article Synopsis
  • Scavenger decapping enzymes (DcpS) play a crucial role in breaking down mRNA by targeting the cap structure m(7)GpppN, which is a common feature in eukaryotic mRNA.
  • The study explores how different substitutions at the N7 position of the guanine in the cap structure affect DcpS from various organisms, including humans and some nematodes, focusing on their rate of hydrolysis and binding affinities.
  • Findings indicate that the DcpS enzyme has a flexible cap-binding pocket, allowing it to accommodate various substrates with different N7 structural modifications for effective hydrolysis.
View Article and Find Full Text PDF
Article Synopsis
  • Synthetic analogs of the mRNA cap structure are crucial for studying cellular processes like translation and are potential targets for cancer therapy.
  • The study focuses on creating new N2-triazole-containing cap analogs that can inhibit protein synthesis, showing effectiveness similar to existing compounds.
  • These newly developed analogs exhibit better cell penetration properties and some have superior inhibitory effects, making them promising candidates for future therapeutic development.
View Article and Find Full Text PDF
Article Synopsis
  • Spliced leader (SL) RNA trans-splicing involves adding a special cap and a 22-nucleotide sequence to the 5' end of mRNAs, creating TMG-capped and MMG-capped mRNAs.
  • Both types of mRNAs exist simultaneously in metazoan cells, with TMG-capped mRNAs needing a specific nucleotide sequence for efficient translation in nematodes.
  • The text outlines a chemical method to prepare and purify different types of capped SL RNAs, including wild-type and mutant versions, with the option to add a 3' biotin tag.
View Article and Find Full Text PDF

Preparative scale synthesis of 14 new N(2)-modified mononucleotide 5' mRNA cap analogues was achieved. The key step involved use of an S(N)Ar reaction with protected 2-fluoro inosine and various primary and secondary amines. The derivatives were tested in a parasitic nematode, Ascaris suum, cell-free system as translation inhibitors.

View Article and Find Full Text PDF

Herein we describe the first simple and short method for specific labeling of mono- and trimethylated dinucleotide mRNA cap analogues with (13)C and (14)C isotopes. The labels were introduced within the cap structures either at the N7 for monomethylguanosine cap or N7 and N2 position for trimethylguanosine cap. The compounds designed for structural and biochemical studies will be useful tools for better understanding the role of the mRNA cap structures in pre-mRNA splicing, nucleocytoplasmic transport, translation initiation and mRNA degradation.

View Article and Find Full Text PDF

Metazoan spliced leader (SL) trans-splicing generates mRNAs with an m(2,2,7)G-cap and a common downstream SL RNA sequence. The mechanism for eIF4E binding an m²²⁷G-cap is unknown. Here, we describe the first structure of an eIF4E with an m(2,2,7)G-cap and compare it to the cognate m⁷G-eIF4E complex.

View Article and Find Full Text PDF
Article Synopsis
  • - Researchers developed new dinucleotide affinity resins specifically designed to purify proteins that bind to the 5' end of mRNA.
  • - These resins utilize either natural or modified cap structures that resist breakdown by enzymes, featuring a unique CH(2) bridge in their triphosphate chain.
  • - The cap analogs are connected to a polymer support (EAH-Sepharose) through a carboxylic group created by modifying the second nucleotide's structure with levulinic acid.
View Article and Find Full Text PDF

mRNAs of primitive eukaryotes such as Caenorhabditis elegans and Ascaris summ possess two different caps at their 5' terminus. They have either a typical cap which consists of 7-methylguanosine linked via a 5',5'-triphosphate bridge to the first transcribed nucleotide (MMG cap) or an atypical hypermethylated form with two additional methyl groups at the N2 position (TMG cap). Studies on interaction between the 5' end of mRNA and proteins that specifically recognize its structure have been carried out for several years and they often require chemically modified cap analogues.

View Article and Find Full Text PDF

The activity of the Caenorhabditis elegans scavenger decapping enzyme (DcpS) on its natural substrates and dinucleotide cap analogs, modified with regard to the nucleoside base or ribose moiety, has been examined. All tested dinucleotides were specifically cleaved between beta- and gamma-phosphate groups in the triphosphate chain. The kinetic parameters of enzymatic hydrolysis (K(m), V(max)) were determined using fluorescence and HPLC methods, as complementary approaches for the kinetic studies of C.

View Article and Find Full Text PDF

Eukaryotic mRNA translation begins with recruitment of the 40S ribosome complex to the mRNA 5' end through the eIF4F initiation complex binding to the 5' m(7)G-mRNA cap. Spliced leader (SL) RNA trans splicing adds a trimethylguanosine (TMG) cap and a sequence, the SL, to the 5' end of mRNAs. Efficient translation of TMG-capped mRNAs in nematodes requires the SL sequence.

View Article and Find Full Text PDF
Article Synopsis
  • The Tgs proteins are enzymes involved in methylating specific RNA nucleotides, particularly in forming the TMG RNA cap.
  • Human Tgs1 can perform two distinct methylation steps on the 7-methylguanosine (m(7)G) cap to create a fully modified TMG cap, while Giardia's Tgs can only create a dimethylguanosine cap and cannot convert it to TMG.
  • The Mimivirus Tgs shares some traits with Giardia's Tgs but can perform a single methylation step without the need for prior modifications, illustrating diverse capabilities within the Tgs enzyme family.
View Article and Find Full Text PDF

The eukaryotic translation initiation factor eIF4E recognizes the mRNA cap, a key step in translation initiation. Here we have characterized eIF4E from the human parasite Schistosoma mansoni. Schistosome mRNAs have either the typical monomethylguanosine (m(7)G) or a trimethylguanosine (m(2,2,7)G) cap derived from spliced leader trans-splicing.

View Article and Find Full Text PDF